Part of the requirement of the MTPConnect funding agreement is that the 6 projects make a tangible difference to the Clinical Trials Sector. Therefore we have to ensure that we do measure and evaluate carefully the true effects of CT:IQ. We know that this is often difficult to measure and will be a long process, with ‘soft’ outcomes such as behaviour and culture shift being the first likely indicators of success. We will be utilising Australian expertise in qualitative and quantitative analysis and will develop objective measures of success as part of the topic selection criteria and project planning. We will also be able to learn from the CTTI US experience who are 10 years into the transformation journey and have developed a range of measures that can be translated as appropriate.